Value of 11C-methionine PET in imaging brain tumours and metastases

  • Andor W. J. M. Glaudemans
  • Roelien H. Enting
  • Mart A. A. M. Heesters
  • Rudi A. J. O. Dierckx
  • Ronald W. J. van Rheenen
  • Annemiek M. E. Walenkamp
  • Riemer H. J. A. Slart
Review Article

Abstract

11C-methionine (MET) is the most popular amino acid tracer used in PET imaging of brain tumours. Because of its characteristics, MET PET provides a high detection rate of brain tumours and good lesion delineation. This review focuses on the role of MET PET in imaging cerebral gliomas. The Introduction provides a clinical overview of what is important in primary brain tumours, recurrent brain tumours and brain metastases. The indications for radiotherapy and the results and problems arising after chemoradiotherapy in relation to imaging (pseudoprogression or radionecrosis) are discussed. The working mechanism, scan interpretation and quantification possibilities of MET PET are then explained. A literature overview is given of the role of MET PET in primary gliomas (diagnostic accuracy, grading, prognosis, assessment of tumour extent, biopsy and radiotherapy planning), in brain metastases, and in the differentiation between tumour recurrence and radiation necrosis. Finally, MET PET is compared to other nuclear imaging possibilities in brain tumour imaging.

Keywords

11C-Methionine MET PET PET tracers Cerebral glioma Brain metastases 

References

  1. 1.
    Rigau V, Zouaoui S, Mathieu-Daude H, Darlix A, Maran A, Tretarre B, et al. French brain tumor database: 5-year histological results on 25 756 cases. Brain Pathol. 2011;21:633–44.PubMedCrossRefGoogle Scholar
  2. 2.
    Louis DN, Ohgaki H, Wiestler OD, Cavanee WK. Classification of tumours of the CNS. Geneva: World Health Organization; 2007.Google Scholar
  3. 3.
    Kros JM. Grading of gliomas: the road from eminence to evidence. J Neuropathol Exp Neurol. 2011;70:101–9.PubMedCrossRefGoogle Scholar
  4. 4.
    Pouratian N, Schiff D. Management of low-grade glioma. Curr Neurol Neurosci Rep. 2010;10:224–31.PubMedCrossRefGoogle Scholar
  5. 5.
    Smith JS, Chang EF, Lamborn KR, Chang SM, Prados MD, Cha S, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol. 2008;26:1338–45.PubMedCrossRefGoogle Scholar
  6. 6.
    Van den Bent MJ, Afra D, de White O, Ben HM, Schraub S, Hoang-Xuan K, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet. 2005;366:985–90.PubMedCrossRefGoogle Scholar
  7. 7.
    Douw L, Klein M, Fagel SS, van den Heuvel J, Taphoorn MJ, Aaronson NK, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurol. 2009;8:810–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Wick W. Anaplastic gliomas: an emerging entity. Eur J Cancer. 2011;47 Suppl 3:S357–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol. 2009;27:5874–80.PubMedCrossRefGoogle Scholar
  10. 10.
    Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, Brachman D, et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group trial 9402. J Clin Oncol. 2006;24:2707–14.PubMedCrossRefGoogle Scholar
  11. 11.
    Stark AM, van de Bergh J, Hedderich J, Mehdorn HM, Nabavi A. Glioblastoma: clinical characteristics, prognostic factors and survival in 492 patients. Clin Neurol Neurosurg. 2012;114:840–5.PubMedCrossRefGoogle Scholar
  12. 12.
    Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery. 2008;62:753–64.PubMedCrossRefGoogle Scholar
  13. 13.
    Stupp R, Hegi ME, Mason WP, Van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10:459–66.PubMedCrossRefGoogle Scholar
  14. 14.
    Jackson RJ, Fuller GN, Abi-Said D, Lang FF, Gokaslan ZL, Shi WM, et al. Limitations of stereotactic biopsy in the initial management of gliomas. Neuro Oncol. 2001;3:193–200.PubMedGoogle Scholar
  15. 15.
    Olar A, Aldape KD. Biomarkers classification and therapeutic decision-making for malignant gliomas. Curr Treat Options Oncol. 2012;13:417–36.PubMedCrossRefGoogle Scholar
  16. 16.
    Hartmann C, Hentschel B, Tatagiba M, Schramm J, Schnell O, Seidel C, et al. Molecular markers in low-grade gliomas: predictive or prognostic? Clin Cancer Res. 2011;17:4588–99.PubMedCrossRefGoogle Scholar
  17. 17.
    Korshunov A, Meyer J, Capper D, Christians A, Remke M, Witt H, et al. Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma. Acta Neuropathol. 2009;118:401–5.PubMedCrossRefGoogle Scholar
  18. 18.
    Hawkins C, Walker E, Mohamed N, Zhang C, Jacob K, Shirinian M, et al. BRAF-KIAA1549 fusion predicts better clinical outcome in pediatric low-grade astrocytoma. Clin Cancer Res. 2011;17:4790–8.PubMedCrossRefGoogle Scholar
  19. 19.
    Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 2006;9:157–73.PubMedCrossRefGoogle Scholar
  20. 20.
    Khasraw M, Simeonovic M, Grommes C. Bevacizumab for the treatment of high-grade glioma. Expert Opin Biol Ther. 2012;12:1101–11.PubMedCrossRefGoogle Scholar
  21. 21.
    Niyazi M, Siefert A, Schwarz SB, Ganswindt U, Kreth FW, Tonn JC, et al. Therapeutic options for recurrent malignant glioma. Radiother Oncol. 2011;98:1–14.PubMedCrossRefGoogle Scholar
  22. 22.
    Fogh SE, Andrews DW, Glass J, Curran W, Glass C, Champ C, et al. Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas. J Clin Oncol. 2010;28:3048–53.PubMedCrossRefGoogle Scholar
  23. 23.
    Yung WK, Prados MD, Yaya-Tur R, Rosenfeld SS, Brada M, Friedman HS, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol. 1999;17:2762–71.PubMedGoogle Scholar
  24. 24.
    Soffietti R, Ruda R, Bradac GB, Schiffer D. PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas. Neurosurgery. 1998;43:1066–73.PubMedCrossRefGoogle Scholar
  25. 25.
    Van den Bent MJ, Taphoorn MJ, Brandes AA, Menten J, Stupp R, Frenay M, et al. Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J Clin Oncol. 2003;21:2525–8.PubMedCrossRefGoogle Scholar
  26. 26.
    Taal W, Dubbink HJ, Zonnenberg CB, Zonnenberg BA, Postma TJ, Gijtenbeek JM, et al. First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response. Neuro Oncol. 2011;13:235–41.PubMedCrossRefGoogle Scholar
  27. 27.
    Johnson JD, Young B. Demographics of brain metastasis. Neurosurg Clin N Am. 1996;7:337–44.PubMedGoogle Scholar
  28. 28.
    Posner JB. Management of brain metastases. Rev Neurol (Paris). 1992;148:477–87.Google Scholar
  29. 29.
    Higer HP, Pedrosa P, Schuth M. MR imaging of cerebral tumors: state of the art and work in progress. Neurosurg Rev. 1989;12:91–106.PubMedCrossRefGoogle Scholar
  30. 30.
    Paterson AH, Agarwal M, Lees A, Hanson J, Szafran O. Brain metastases in breast cancer patients receiving adjuvant chemotherapy. Cancer. 1982;49:651–4.PubMedCrossRefGoogle Scholar
  31. 31.
    Sundermeyer ML, Meropol NJ, Rogatko A, Wang H, Cohen SJ. Changing patterns of bone and brain metastases in patients with colorectal cancer. Clin Colorectal Cancer. 2005;5:108–13.PubMedCrossRefGoogle Scholar
  32. 32.
    Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol. 2004;22:2865–72.PubMedCrossRefGoogle Scholar
  33. 33.
    Schouten LJ, Rutten J, Huveneers HA, Twijnstra A. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer. 2002;94:2698–705.PubMedCrossRefGoogle Scholar
  34. 34.
    Sawaya R, Bindal RK, Lang FF. Brain tumors, 2nd edition: an encyclopedic approach. London: Churchill Livingstone; 2001.Google Scholar
  35. 35.
    Gavrilovic IT, Posner JB. Brain metastases: epidemiology and pathophysiology. J Neurooncol. 2005;75:5–14.PubMedCrossRefGoogle Scholar
  36. 36.
    Delattre JY, Krol G, Thaler HT, Posner JB. Distribution of brain metastases. Arch Neurol. 1988;45:741–4.PubMedCrossRefGoogle Scholar
  37. 37.
    Bleehen NM, Wiltshire CR, Plowman PN, Watson JV, Gleave JR, Holmes AE, et al. A randomized study of misonidazole and radiotherapy for grade 3 and 4 cerebral astrocytoma. Br J Cancer. 1981;43:436–42.PubMedCrossRefGoogle Scholar
  38. 38.
    Chang CH, Horton J, Schoenfeld D, Salazer O, Perez-Tamayo R, Kramer S, et al. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study. Cancer. 1983;52:997–1007.PubMedCrossRefGoogle Scholar
  39. 39.
    Walker MD, Strike TA, Sheline GE. An analysis of dose–effect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys. 1979;5:1725–31.PubMedCrossRefGoogle Scholar
  40. 40.
    Keime-Guibert F, Chinot O, Taillandier L, Cartalat-Carel S, Frenay M, Kantor G, et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med. 2007;356:1527–35.PubMedCrossRefGoogle Scholar
  41. 41.
    Kristiansen K, Hagen S, Kollevold T, Torvik A, Holme I, Nesbakken R, et al. Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer. 1981;47:649–52.PubMedCrossRefGoogle Scholar
  42. 42.
    Sheline GE. Radiotherapy for high grade gliomas. Int J Radiat Oncol Biol Phys. 1990;18:793–803.PubMedCrossRefGoogle Scholar
  43. 43.
    Walker MD, Alexander Jr E, Hunt WE, MacCarty CS, Mahaley Jr MS, Mealey Jr J, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg. 1978;49:333–43.PubMedCrossRefGoogle Scholar
  44. 44.
    McAleese JJ, Stenning SP, Ashley S, Traish D, Hines F, Sardell S, et al. Hypofractionated radiotherapy for poor prognosis malignant glioma: matched pair survival analysis with MRC controls. Radiother Oncol. 2003;67:177–82.PubMedCrossRefGoogle Scholar
  45. 45.
    Roa W, Brasher PM, Bauman G, Anthes M, Bruera E, Chan A, et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol. 2004;22:1583–8.PubMedCrossRefGoogle Scholar
  46. 46.
    Slotman BJ, Kralendonk JH, van Alphen HA, Kamphorst W, Karim AB. Hypofractionated radiation therapy in patients with glioblastoma multiforme: results of treatment and impact of prognostic factors. Int J Radiat Oncol Biol Phys. 1996;34:895–8.PubMedCrossRefGoogle Scholar
  47. 47.
    Cairncross G, Jenkins R. Gliomas with 1p/19q codeletion: a.k.a. oligodendroglioma. Cancer J. 2008;14:352–7.PubMedCrossRefGoogle Scholar
  48. 48.
    Karim AB, Maat B, Hatlevoll R, Menten J, Rutten EH, Thomas DG, et al. A randomized trial on dose–response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) study 22844. Int J Radiat Oncol Biol Phys. 1996;36:549–56.PubMedCrossRefGoogle Scholar
  49. 49.
    Shaw E, Arusell R, Scheithauer B, O’Fallon J, O’Neill B, Dinapoli R, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J Clin Oncol. 2002;20:2267–76.PubMedCrossRefGoogle Scholar
  50. 50.
    Lagerwaard FJ, Levendag PC, Nowak PJ, Eijkenboom WM, Hanssens PE, Schmitz PI. Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. Int J Radiat Oncol Biol Phys. 1999;43:795–803.PubMedCrossRefGoogle Scholar
  51. 51.
    Pease NJ, Edwards A, Moss LJ. Effectiveness of whole brain radiotherapy in the treatment of brain metastases: a systematic review. Palliat Med. 2005;19:288–99.PubMedCrossRefGoogle Scholar
  52. 52.
    Tsao MN, Sultanem K, Chiu D, Copps F, Dixon P, Easton D, et al. Supportive care management of brain metastases: what is known and what we need to know. Conference proceedings of the National Cancer Institute of Canada (NCIC) workshop on symptom control in radiation oncology. Clin Oncol (R Coll Radiol). 2003;15:429–34.CrossRefGoogle Scholar
  53. 53.
    Tsao MN, Lloyd N, Wong R, Chow E, Rakovitch E, Laperriere N. Whole brain radiotherapy for the treatment of multiple brain metastases. Cochrane Database Syst Rev. 2006;CD003869.Google Scholar
  54. 54.
    Wong J, Hird A, Kirou-Mauro A, Napolskikh J, Chow E. Quality of life in brain metastases radiation trials: a literature review. Curr Oncol. 2008;15:25–45.PubMedCrossRefGoogle Scholar
  55. 55.
    Addeo R, Caraglia M, Faiola V, Capasso E, Vincenzi B, Montella L, et al. Concomitant treatment of brain metastasis with whole brain radiotherapy [WBRT] and temozolomide [TMZ] is active and improves quality of life. BMC Cancer. 2007;7:18.PubMedCrossRefGoogle Scholar
  56. 56.
    Bezjak A, Adam J, Barton R, Panzarella T, Laperriere N, Wong CS, et al. Symptom response after palliative radiotherapy for patients with brain metastases. Eur J Cancer. 2002;38:487–96.PubMedCrossRefGoogle Scholar
  57. 57.
    Chang EL, Wefel JS, Hess KR, Allen PK, Lang FF, Kornguth DG, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol. 2009;10:1037–44.PubMedCrossRefGoogle Scholar
  58. 58.
    Hird A, Wong J, Zhang L, Tsao M, Barnes E, Danjoux C, et al. Exploration of symptoms clusters within cancer patients with brain metastases using the Spitzer Quality of Life Index. Support Care Cancer. 2010;18:335–42.PubMedCrossRefGoogle Scholar
  59. 59.
    Kondziolka D, Niranjan A, Flickinger JC, Lunsford LD. Radiosurgery with or without whole-brain radiotherapy for brain metastases: the patients’ perspective regarding complications. Am J Clin Oncol. 2005;28:173–9.PubMedCrossRefGoogle Scholar
  60. 60.
    Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet. 2004;363:1665–72.PubMedCrossRefGoogle Scholar
  61. 61.
    Dhermain FG, Hau P, Lanfermann H, Jacobs AH, Van den Bent MJ. Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas. Lancet Neurol. 2010;9:906–20.PubMedCrossRefGoogle Scholar
  62. 62.
    Van den Bent MJ, Wefel JS, Schiff D, Taphoorn MJ, Jaeckle K, Junck L, et al. Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol. 2011;12:583–93.PubMedCrossRefGoogle Scholar
  63. 63.
    Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28:1963–72.PubMedCrossRefGoogle Scholar
  64. 64.
    Mandonnet E, Delattre JY, Tanguy ML, Swanson KR, Carpentier AF, Duffau H, et al. Continuous growth of mean tumor diameter in a subset of grade II gliomas. Ann Neurol. 2003;53:524–8.PubMedCrossRefGoogle Scholar
  65. 65.
    Sze G, Milano E, Johnson C, Heier L. Detection of brain metastases: comparison of contrast-enhanced MR with unenhanced MR and enhanced CT. AJNR Am J Neuroradiol. 1990;11:785–91.PubMedGoogle Scholar
  66. 66.
    Schaefer PW, Budzik Jr RF, Gonzalez RG. Imaging of cerebral metastases. Neurosurg Clin N Am. 1996;7:393–423.PubMedGoogle Scholar
  67. 67.
    Oude Munnink TH, Nagengast WB, Brouwers AH, Schroder CP, Hospers GA, Lub-de Hooge MN, et al. Molecular imaging of breast cancer. Breast. 2009;18 Suppl 3:S66–73.PubMedCrossRefGoogle Scholar
  68. 68.
    Dijkers EC, Oude Munnink TH, Kosterink JG, Brouwers AH, Jager PL, de Jong JR, et al. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther. 2010;87:586–92.PubMedCrossRefGoogle Scholar
  69. 69.
    Long DM. Capillary ultrastructure in human metastatic brain tumors. J Neurosurg. 1979;51:53–8.PubMedCrossRefGoogle Scholar
  70. 70.
    Brandsma D, Van den Bent MJ. Pseudoprogression and pseudoresponse in the treatment of gliomas. Curr Opin Neurol. 2009;22:633–8.PubMedCrossRefGoogle Scholar
  71. 71.
    Brandsma D, Stalpers L, Taal W, Sminia P, Van den Bent MJ. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol. 2008;9:453–61.PubMedCrossRefGoogle Scholar
  72. 72.
    van Waarde A, Elsinga PH. Proliferation markers for the differential diagnosis of tumor and inflammation. Curr Pharm Des. 2008;14:3326–39.PubMedCrossRefGoogle Scholar
  73. 73.
    Langstrom B, Antoni G, Gullberg P, Halldin C, Malmborg P, Nagren K, et al. Synthesis of L- and D-[methyl-11C]methionine. J Nucl Med. 1987;28:1037–40.PubMedGoogle Scholar
  74. 74.
    Bergstrom M, Lundqvist H, Ericson K, Lilja A, Johnstrom P, Langstrom B, et al. Comparison of the accumulation kinetics of L-(methyl-11C)-methionine and D-(methyl-11C)-methionine in brain tumors studied with positron emission tomography. Acta Radiol. 1987;28:225–9.PubMedCrossRefGoogle Scholar
  75. 75.
    Kubota K. From tumor biology to clinical PET: a review of positron emission tomography (PET) in oncology. Ann Nucl Med. 2001;15:471–86.PubMedCrossRefGoogle Scholar
  76. 76.
    Jager PL, Vaalburg W, Pruim J, de Vries EG, Langen KJ, Piers DA. Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med. 2001;42:432–45.PubMedGoogle Scholar
  77. 77.
    Coope DJ, Cizek J, Eggers C, Vollmar S, Heiss WD, Herholz K. Evaluation of primary brain tumors using 11C-methionine PET with reference to a normal methionine uptake map. J Nucl Med. 2007;48:1971–80.PubMedCrossRefGoogle Scholar
  78. 78.
    Nagata T, Tsuyuguchi N, Uda T, Terakawa Y, Takami T, Ohata K. Examination of 11C-methionine metabolism by the standardized uptake value in the normal brain of children. J Nucl Med. 2011;52:201–5.PubMedCrossRefGoogle Scholar
  79. 79.
    Moulin-Romsee G, D’Hondt E, de Groot T, Goffin J, Sciot R, Mortelmans L, et al. Non-invasive grading of brain tumours using dynamic amino acid PET imaging: does it work for 11C-methionine? Eur J Nucl Med Mol Imaging. 2007;34:2082–7.PubMedCrossRefGoogle Scholar
  80. 80.
    Stober B, Tanase U, Herz M, Seidl C, Schwaiger M, Senekowitsch-Schmidtke R. Differentiation of tumour and inflammation: characterisation of [methyl-3H]methionine (MET) and O-(2-[18F]fluoroethyl)-L-tyrosine (FET) uptake in human tumour and inflammatory cells. Eur J Nucl Med Mol Imaging. 2006;33:932–9.PubMedCrossRefGoogle Scholar
  81. 81.
    Kracht LW, Friese M, Herholz K, Schroeder R, Bauer B, Jacobs A, et al. Methyl-[11C]-l-methionine uptake as measured by positron emission tomography correlates to microvessel density in patients with glioma. Eur J Nucl Med Mol Imaging. 2003;30:868–73.PubMedCrossRefGoogle Scholar
  82. 82.
    Spaeth N, Wyss MT, Pahnke J, Biollaz G, Lutz A, Goepfert K, et al. Uptake of 18F-fluorocholine, 18F-fluoro-ethyl-L-tyrosine and 18F-fluoro-2-deoxyglucose in F98 gliomas in the rat. Eur J Nucl Med Mol Imaging. 2006;33:673–82.PubMedCrossRefGoogle Scholar
  83. 83.
    Tsuyuguchi N, Sunada I, Iwai Y, Yamanaka K, Tanaka K, Takami T, et al. Methionine positron emission tomography of recurrent metastatic brain tumor and radiation necrosis after stereotactic radiosurgery: is a differential diagnosis possible? J Neurosurg. 2003;98:1056–64.PubMedCrossRefGoogle Scholar
  84. 84.
    Becherer A, Karanikas G, Szabo M, Zettinig G, Asenbaum S, Marosi C, et al. Brain tumour imaging with PET: a comparison between [18F]fluorodopa and [11C]methionine. Eur J Nucl Med Mol Imaging. 2003;30:1561–7.PubMedCrossRefGoogle Scholar
  85. 85.
    Braun V, Dempf S, Weller R, Reske SN, Schachenmayr W, Richter HP. Cranial neuronavigation with direct integration of (11)C methionine positron emission tomography (PET) data – results of a pilot study in 32 surgical cases. Acta Neurochir (Wien). 2002;144:777–82.CrossRefGoogle Scholar
  86. 86.
    Chung JK, Kim YK, Kim SK, Lee YJ, Paek S, Yeo JS, et al. Usefulness of 11C-methionine PET in the evaluation of brain lesions that are hypo- or isometabolic on 18F-FDG PET. Eur J Nucl Med Mol Imaging. 2002;29:176–82.PubMedCrossRefGoogle Scholar
  87. 87.
    Galldiks N, Kracht LW, Berthold F, Miletic H, Klein JC, Herholz K, et al. [11C]-L-methionine positron emission tomography in the management of children and young adults with brain tumors. J Neurooncol. 2010;96:231–9.PubMedCrossRefGoogle Scholar
  88. 88.
    Hatakeyama T, Kawai N, Nishiyama Y, Yamamoto Y, Sasakawa Y, Ichikawa T, et al. 11C-methionine (MET) and 18F-fluorothymidine (FLT) PET in patients with newly diagnosed glioma. Eur J Nucl Med Mol Imaging. 2008;35:2009–17.PubMedCrossRefGoogle Scholar
  89. 89.
    Herholz K, Holzer T, Bauer B, Schroder R, Voges J, Ernestus RI, et al. 11C-methionine PET for differential diagnosis of low-grade gliomas. Neurology. 1998;50:1316–22.PubMedCrossRefGoogle Scholar
  90. 90.
    Jacobs AH, Thomas A, Kracht LW, Li H, Dittmar C, Garlip G, et al. 18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors. J Nucl Med. 2005;46:1948–58.PubMedGoogle Scholar
  91. 91.
    Kracht LW, Miletic H, Busch S, Jacobs AH, Voges J, Hoevels M, et al. Delineation of brain tumor extent with [11C]L-methionine positron emission tomography: local comparison with stereotactic histopathology. Clin Cancer Res. 2004;10:7163–70.PubMedCrossRefGoogle Scholar
  92. 92.
    Li DL, Xu YK, Wang QS, Wu HB, Li HS. 11C-methionine and 18F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of patients with suspected primary and residual/recurrent gliomas. Chin Med J (Engl). 2012;125:91–6.Google Scholar
  93. 93.
    Massager N, David P, Goldman S, Pirotte B, Wikler D, Salmon I, et al. Combined magnetic resonance imaging- and positron emission tomography-guided stereotactic biopsy in brainstem mass lesions: diagnostic yield in a series of 30 patients. J Neurosurg. 2000;93:951–7.PubMedCrossRefGoogle Scholar
  94. 94.
    Nuutinen J, Sonninen P, Lehikoinen P, Sutinen E, Valavaara R, Eronen E, et al. Radiotherapy treatment planning and long-term follow-up with [11C]methionine PET in patients with low-grade astrocytoma. Int J Radiat Oncol Biol Phys. 2000;48:43–52.PubMedCrossRefGoogle Scholar
  95. 95.
    Ullrich RT, Kracht L, Brunn A, Herholz K, Frommolt P, Miletic H, et al. Methyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients with glioma. J Nucl Med. 2009;50:1962–8.PubMedCrossRefGoogle Scholar
  96. 96.
    Yamamoto Y, Nishiyama Y, Kimura N, Kameyama R, Kawai N, Hatakeyama T, et al. 11C-acetate PET in the evaluation of brain glioma: comparison with 11C-methionine and 18F-FDG-PET. Mol Imaging Biol. 2008;10:281–7.PubMedCrossRefGoogle Scholar
  97. 97.
    Yamane T, Sakamoto S, Senda M. Clinical impact of (11)C-methionine PET on expected management of patients with brain neoplasm. Eur J Nucl Med Mol Imaging. 2010;37:685–90.PubMedCrossRefGoogle Scholar
  98. 98.
    Kato T, Shinoda J, Nakayama N, Miwa K, Okumura A, Yano H, et al. Metabolic assessment of gliomas using 11C-methionine, [18F] fluorodeoxyglucose, and 11C-choline positron-emission tomography. AJNR Am J Neuroradiol. 2008;29:1176–82.PubMedCrossRefGoogle Scholar
  99. 99.
    Nariai T, Tanaka Y, Wakimoto H, Aoyagi M, Tamaki M, Ishiwata K, et al. Usefulness of L-[methyl-11C]methionine-positron emission tomography as a biological monitoring tool in the treatment of glioma. J Neurosurg. 2005;103:498–507.PubMedCrossRefGoogle Scholar
  100. 100.
    Sadeghi N, Salmon I, Decaestecker C, Levivier M, Metens T, Wikler D, et al. Stereotactic comparison among cerebral blood volume, methionine uptake, and histopathology in brain glioma. AJNR Am J Neuroradiol. 2007;28:455–61.PubMedGoogle Scholar
  101. 101.
    Sasaki M, Kuwabara Y, Yoshida T, Nakagawa M, Fukumura T, Mihara F, et al. A comparative study of thallium-201 SPET, carbon-11 methionine PET and fluorine-18 fluorodeoxyglucose PET for the differentiation of astrocytic tumours. Eur J Nucl Med. 1998;25:1261–9.PubMedCrossRefGoogle Scholar
  102. 102.
    Sato N, Suzuki M, Kuwata N, Kuroda K, Wada T, Beppu T, et al. Evaluation of the malignancy of glioma using 11C-methionine positron emission tomography and proliferating cell nuclear antigen staining. Neurosurg Rev. 1999;22:210–4.PubMedCrossRefGoogle Scholar
  103. 103.
    Shinozaki N, Uchino Y, Yoshikawa K, Matsutani T, Hasegawa A, Saeki N, et al. Discrimination between low-grade oligodendrogliomas and diffuse astrocytoma with the aid of 11C-methionine positron emission tomography. J Neurosurg. 2011;114:1640–7.PubMedCrossRefGoogle Scholar
  104. 104.
    Ceyssens S, Van Laere K, de Groot T, Goffin J, Bormans G, Mortelmans L. [11C]methionine PET, histopathology, and survival in primary brain tumors and recurrence. AJNR Am J Neuroradiol. 2006;27:1432–7.PubMedGoogle Scholar
  105. 105.
    Kato T, Shinoda J, Oka N, Miwa K, Nakayama N, Yano H, et al. Analysis of 11C-methionine uptake in low-grade gliomas and correlation with proliferative activity. AJNR Am J Neuroradiol. 2008;29:1867–71.PubMedCrossRefGoogle Scholar
  106. 106.
    Kaschten B, Stevenaert A, Sadzot B, Deprez M, Degueldre C, Del FG, et al. Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine. J Nucl Med. 1998;39:778–85.PubMedGoogle Scholar
  107. 107.
    Smits A, Westerberg E, Ribom D. Adding 11C-methionine PET to the EORTC prognostic factors in grade 2 gliomas. Eur J Nucl Med Mol Imaging. 2008;35:65–71.PubMedCrossRefGoogle Scholar
  108. 108.
    Kim S, Chung JK, Im SH, Jeong JM, Lee DS, Kim DG, et al. 11C-methionine PET as a prognostic marker in patients with glioma: comparison with 18F-FDG PET. Eur J Nucl Med Mol Imaging. 2005;32:52–9.PubMedCrossRefGoogle Scholar
  109. 109.
    Ribom D, Eriksson A, Hartman M, Engler H, Nilsson A, Langstrom B, et al. Positron emission tomography (11)C-methionine and survival in patients with low-grade gliomas. Cancer. 2001;92:1541–9.PubMedCrossRefGoogle Scholar
  110. 110.
    Singhal T, Narayanan TK, Jain V, Mukherjee J, Mantil J. 11C-L-methionine positron emission tomography in the clinical management of cerebral gliomas. Mol Imaging Biol. 2008;10:1–18.PubMedCrossRefGoogle Scholar
  111. 111.
    Giglio P, Gilbert MR. Cerebral radiation necrosis. Neurologist. 2003;9:180–8.PubMedCrossRefGoogle Scholar
  112. 112.
    Lee IH, Piert M, Gomez-Hassan D, Junck L, Rogers L, Hayman J, et al. Association of 11C-methionine PET uptake with site of failure after concurrent temozolomide and radiation for primary glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2009;73:479–85.PubMedCrossRefGoogle Scholar
  113. 113.
    Pirotte B, Goldman S, Dewitte O, Massager N, Wikler D, Lefranc F, et al. Integrated positron emission tomography and magnetic resonance imaging-guided resection of brain tumors: a report of 103 consecutive procedures. J Neurosurg. 2006;104:238–53.PubMedCrossRefGoogle Scholar
  114. 114.
    Mineura K, Sasajima T, Suda Y, Kowada M, Shishido F, Uemura K. Amino acid study of cerebral gliomas using positron emission tomography – analysis of (11C-methyl)-L-methionine uptake index. Neurol Med Chir (Tokyo). 1990;30:997–1002.CrossRefGoogle Scholar
  115. 115.
    Mosskin M, Bergstrom M, Collins VP, Ehrin E, Eriksson L, von Holst H, et al. Positron emission tomography with 11C-methionine of intracranial tumours compared with histology of multiple biopsies. Acta Radiol Suppl. 1986;369:157–60.PubMedGoogle Scholar
  116. 116.
    Mosskin M, Ericson K, Hindmarsh T, von Holst H, Collins VP, Bergstrom M, et al. Positron emission tomography compared with magnetic resonance imaging and computed tomography in supratentorial gliomas using multiple stereotactic biopsies as reference. Acta Radiol. 1989;30:225–32.PubMedCrossRefGoogle Scholar
  117. 117.
    Voges J, Herholz K, Holzer T, Wurker M, Bauer B, Pietrzyk U, et al. 11C-methionine and 18F-2-fluorodeoxyglucose positron emission tomography: a tool for diagnosis of cerebral glioma and monitoring after brachytherapy with 125I seeds. Stereotact Funct Neurosurg. 1997;69:129–35.PubMedCrossRefGoogle Scholar
  118. 118.
    Gumprecht H, Grosu AL, Souvatsoglou M, Dzewas B, Weber WA, Lumenta CB. 11C-methionine positron emission tomography for preoperative evaluation of suggestive low-grade gliomas. Zentralbl Neurochir. 2007;68:19–23.PubMedCrossRefGoogle Scholar
  119. 119.
    Pirotte B, Goldman S, Massager N, David P, Wikler D, Lipszyc M, et al. Combined use of 18F-fluorodeoxyglucose and 11C-methionine in 45 positron emission tomography-guided stereotactic brain biopsies. J Neurosurg. 2004;101:476–83.PubMedCrossRefGoogle Scholar
  120. 120.
    Pirotte B, Goldman S, Massager N, David P, Wikler D, Vandesteene A, et al. Comparison of 18F-FDG and 11C-methionine for PET-guided stereotactic brain biopsy of gliomas. J Nucl Med. 2004;45:1293–8.PubMedGoogle Scholar
  121. 121.
    Grosu AL, Astner ST, Riedel E, Nieder C, Wiedenmann N, Heinemann F, et al. An interindividual comparison of O-(2-[18F]fluoroethyl)-L-tyrosine (FET)- and L-[methyl-11C]methionine (MET)-PET in patients with brain gliomas and metastases. Int J Radiat Oncol Biol Phys. 2011;81:1049–58.PubMedCrossRefGoogle Scholar
  122. 122.
    Sonoda Y, Kumabe T, Takahashi T, Shirane R, Yoshimoto T. Clinical usefulness of 11C-MET PET and 201Tl SPECT for differentiation of recurrent glioma from radiation necrosis. Neurol Med Chir (Tokyo). 1998;38:342–7.CrossRefGoogle Scholar
  123. 123.
    Terakawa Y, Tsuyuguchi N, Iwai Y, Yamanaka K, Higashiyama S, Takami T, et al. Diagnostic accuracy of 11C-methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy. J Nucl Med. 2008;49:694–9.PubMedCrossRefGoogle Scholar
  124. 124.
    Tripathi M, Sharma R, Varshney R, Jaimini A, Jain J, Souza MM, et al. Comparison of F-18 FDG and C-11 methionine PET/CT for the evaluation of recurrent primary brain tumors. Clin Nucl Med. 2012;37:158–63.PubMedCrossRefGoogle Scholar
  125. 125.
    Tsuyuguchi N, Takami T, Sunada I, Iwai Y, Yamanaka K, Tanaka K, et al. Methionine positron emission tomography for differentiation of recurrent brain tumor and radiation necrosis after stereotactic radiosurgery – in malignant glioma. Ann Nucl Med. 2004;18:291–6.PubMedCrossRefGoogle Scholar
  126. 126.
    Okamoto S, Shiga T, Hattori N, Kubo N, Takei T, Katoh N, et al. Semiquantitative analysis of C-11 methionine PET may distinguish brain tumor recurrence from radiation necrosis even in small lesions. Ann Nucl Med. 2011;25:213–20.PubMedCrossRefGoogle Scholar
  127. 127.
    Van Laere K, Ceyssens S, Van Calenbergh F, de Groot T, Menten J, Flamen P, et al. Direct comparison of 18F-FDG and 11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value. Eur J Nucl Med Mol Imaging. 2005;32:39–51.PubMedCrossRefGoogle Scholar
  128. 128.
    Viader F, Derlon JM, Petit-Taboue MC, Shishido F, Hubert P, Houtteville JP, et al. Recurrent oligodendroglioma diagnosed with 11C-L-methionine and PET: a case report. Eur Neurol. 1993;33:248–51.PubMedCrossRefGoogle Scholar
  129. 129.
    Lilja A, Lundqvist H, Olsson Y, Spannare B, Gullberg P, Langstrom B. Positron emission tomography and computed tomography in differential diagnosis between recurrent or residual glioma and treatment-induced brain lesions. Acta Radiol. 1989;30:121–8.PubMedCrossRefGoogle Scholar
  130. 130.
    Pötzi C, Becherer A, Marosi C, Karanikas G, Szabo M, Dudczak R, et al. [11C] methionine and [18F] fluorodeoxyglucose PET in the follow-up of glioblastoma multiforme. J Neurooncol. 2007;84:305–14.PubMedCrossRefGoogle Scholar
  131. 131.
    Kim YH, Oh SW, Lim YJ, Park CK, Lee SH, Kang KW, et al. Differentiating radiation necrosis from tumor recurrence in high-grade gliomas: assessing the efficacy of 18F-FDG PET, 11C-methionine PET and perfusion MRI. Clin Neurol Neurosurg. 2010;112:758–65.PubMedCrossRefGoogle Scholar
  132. 132.
    Dandois V, Rommel D, Renard L, Jamart J, Cosnard G. Substitution of 11C-methionine PET by perfusion MRI during the follow-up of treated high-grade gliomas: preliminary results in clinical practice. J Neuroradiol. 2010;37:89–97.PubMedCrossRefGoogle Scholar
  133. 133.
    Rottenburger C, Hentschel M, Kelly T, Trippel M, Brink I, Reithmeier T, et al. Comparison of C-11 methionine and C-11 choline for PET imaging of brain metastases: a prospective pilot study. Clin Nucl Med. 2011;36:639–42.PubMedCrossRefGoogle Scholar
  134. 134.
    Miwa K, Matsuo M, Shinoda J, Aki T, Yonezawa S, Ito T, et al. Clinical value of [(11)C]methionine PET for stereotactic radiation therapy with intensity modulated radiation therapy to metastatic brain tumors. Int J Radiat Oncol Biol Phys. 2012;84:1139–44.PubMedCrossRefGoogle Scholar
  135. 135.
    Matsuo M, Miwa K, Shinoda J, Kako N, Nishibori H, Sakurai K, et al. Target definition by C11-methionine-PET for the radiotherapy of brain metastases. Int J Radiat Oncol Biol Phys. 2009;74:714–22.PubMedCrossRefGoogle Scholar
  136. 136.
    Tang BN, Van SG, Devriendt D, Sadeghi N, Dewitte O, Massager N, et al. Three-dimensional Gaussian model to define brain metastasis limits on 11C-methionine PET. Radiother Oncol. 2008;89:270–7.PubMedCrossRefGoogle Scholar
  137. 137.
    Gulyas B, Nyary I, Borbely K. FDG, MET or CHO? The quest for the optimal PET tracer for glioma imaging continues. Nat Clin Pract Neurol. 2008;4:470–1.PubMedCrossRefGoogle Scholar
  138. 138.
    Crippa F, Alessi A, Serafini GL. PET with radiolabeled aminoacid. Q J Nucl Med Mol Imaging. 2012;56:151–62.PubMedGoogle Scholar
  139. 139.
    Ogawa T, Kanno I, Shishido F, Inugami A, Higano S, Fujita H, et al. Clinical value of PET with 18F-fluorodeoxyglucose and L-methyl-11C-methionine for diagnosis of recurrent brain tumor and radiation injury. Acta Radiol. 1991;32:197–202.PubMedCrossRefGoogle Scholar
  140. 140.
    Ogawa T, Inugami A, Hatazawa J, Kanno I, Murakami M, Yasui N, et al. Clinical positron emission tomography for brain tumors: comparison of fludeoxyglucose F18 and L-methyl-11C-methionine. AJNR Am J Neuroradiol. 1996;17:345–53.PubMedGoogle Scholar
  141. 141.
    Goldman S, Levivier M, Pirotte B, Brucher JM, Wikler D, Damhaut P, et al. Regional methionine and glucose uptake in high-grade gliomas: a comparative study on PET-guided stereotactic biopsy. J Nucl Med. 1997;38:1459–62.PubMedGoogle Scholar
  142. 142.
    Wester HJ, Herz M, Weber W, Heiss P, Senekowitsch-Schmidtke R, Schwaiger M, et al. Synthesis and radiopharmacology of O-(2-[18F]fluoroethyl)-L-tyrosine for tumor imaging. J Nucl Med. 1999;40:205–12.PubMedGoogle Scholar
  143. 143.
    Weber WA, Wester HJ, Grosu AL, Herz M, Dzewas B, Feldmann HJ, et al. O-(2-[18F]fluoroethyl)-L-tyrosine and L-[methyl-11C]methionine uptake in brain tumours: initial results of a comparative study. Eur J Nucl Med. 2000;27:542–9.PubMedCrossRefGoogle Scholar
  144. 144.
    Agool A, Glaudemans AW, Boersma HH, Dierckx RA, Vellenga E, Slart RH. Radionuclide imaging of bone marrow disorders. Eur J Nucl Med Mol Imaging. 2011;38:166–78.PubMedCrossRefGoogle Scholar
  145. 145.
    Langen KJ, Ziemons K, Kiwit JC, Herzog H, Kuwert T, Bock WJ, et al. 3-[123I]iodo-alpha-methyltyrosine and [methyl-11C]-L-methionine uptake in cerebral gliomas: a comparative study using SPECT and PET. J Nucl Med. 1997;38:517–22.PubMedGoogle Scholar
  146. 146.
    Ribom D, Schoenmaekers M, Engler H, Smits A. Evaluation of 11C-methionine PET as a surrogate endpoint after treatment of grade 2 gliomas. J Neurooncol. 2005;71:325–32.PubMedCrossRefGoogle Scholar
  147. 147.
    Glaudemans AW, Quintero AM, Signore A. PET/MRI in infectious and inflammatory diseases: will it be a useful improvement? Eur J Nucl Med Mol Imaging. 2012;39:745–9.PubMedCrossRefGoogle Scholar
  148. 148.
    Boss A, Bisdas S, Kolb A, Hofmann M, Ernemann U, Claussen CD, et al. Hybrid PET/MRI of intracranial masses: initial experiences and comparison to PET/CT. J Nucl Med. 2010;51:1198–205.PubMedCrossRefGoogle Scholar
  149. 149.
    Okubo S, Zhen HN, Kawai N, Nishiyama Y, Haba R, Tamiya T. Correlation of L-methyl-11C-methionine (MET) uptake with L-type amino acid transporter 1 in human gliomas. J Neurooncol. 2010;99:217–25.PubMedCrossRefGoogle Scholar
  150. 150.
    Sadeghi N, Salmon I, Tang BN, Denolin V, Levivier M, Wikler D, et al. Correlation between dynamic susceptibility contrast perfusion MRI and methionine metabolism in brain gliomas: preliminary results. J Magn Reson Imaging. 2006;24:989–94.PubMedCrossRefGoogle Scholar
  151. 151.
    Kameyama M, Shirane R, Itoh J, Sato K, Katakura R, Yoshimoto T, et al. The accumulation of 11C-methionine in cerebral glioma patients studied with PET. Acta Neurochir (Wien). 1990;104:8–12.CrossRefGoogle Scholar
  152. 152.
    Grosu AL, Weber WA, Riedel E, Jeremic B, Nieder C, Franz M, et al. L-(methyl-11C) methionine positron emission tomography for target delineation in resected high-grade gliomas before radiotherapy. Int J Radiat Oncol Biol Phys. 2005;63:64–74.PubMedCrossRefGoogle Scholar
  153. 153.
    Derlon JM, Petit-Taboue MC, Chapon F, Beaudouin V, Noel MH, Creveuil C, et al. The in vivo metabolic pattern of low-grade brain gliomas: a positron emission tomographic study using 18F-fluorodeoxyglucose and 11C-L-methylmethionine. Neurosurgery. 1997;40:276–87.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • Andor W. J. M. Glaudemans
    • 1
  • Roelien H. Enting
    • 2
  • Mart A. A. M. Heesters
    • 3
  • Rudi A. J. O. Dierckx
    • 1
    • 4
  • Ronald W. J. van Rheenen
    • 1
  • Annemiek M. E. Walenkamp
    • 5
  • Riemer H. J. A. Slart
    • 1
  1. 1.Department of Nuclear Medicine and Molecular Imaging, University Medical Center GroningenUniversity of GroningenGroningenThe Netherlands
  2. 2.Department of Neurology, University Medical Center GroningenUniversity of GroningenGroningenThe Netherlands
  3. 3.Department of Radiotherapy, University Medical Center GroningenUniversity of GroningenGroningenThe Netherlands
  4. 4.Ghent UniversityGhentBelgium
  5. 5.Department of Medical Oncology, University Medical Center GroningenUniversity of GroningenGroningenThe Netherlands

Personalised recommendations